Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma

Sorafenib is a multiple kinase inhibitor which targets Raf kinases, VEGFR, and PDGFR and is approved for the treatment of hepatocellular carcinoma (HCC). Previously, we found that p-STAT3 is a major target of SC-43, a sorafenib derivative. In this study, we report that SC-43-induced apoptosis in cho...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Ming-Hung, Chen, Li-Ju, Chen, Yen-Lin, Tsai, Ming-Shen, Shiau, Chung-Wai, Chao, Tzu-I, Liu, Chun-Yu, Kao, Jia-Horng, Chen, Kuen-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630313/
https://www.ncbi.nlm.nih.gov/pubmed/29029413
http://dx.doi.org/10.18632/oncotarget.17779
_version_ 1783269197013319680
author Hu, Ming-Hung
Chen, Li-Ju
Chen, Yen-Lin
Tsai, Ming-Shen
Shiau, Chung-Wai
Chao, Tzu-I
Liu, Chun-Yu
Kao, Jia-Horng
Chen, Kuen-Feng
author_facet Hu, Ming-Hung
Chen, Li-Ju
Chen, Yen-Lin
Tsai, Ming-Shen
Shiau, Chung-Wai
Chao, Tzu-I
Liu, Chun-Yu
Kao, Jia-Horng
Chen, Kuen-Feng
author_sort Hu, Ming-Hung
collection PubMed
description Sorafenib is a multiple kinase inhibitor which targets Raf kinases, VEGFR, and PDGFR and is approved for the treatment of hepatocellular carcinoma (HCC). Previously, we found that p-STAT3 is a major target of SC-43, a sorafenib derivative. In this study, we report that SC-43-induced apoptosis in cholangiocarcinoma (CCA) via a novel mechanism. Three CCA cell lines (HuCCT-1, KKU-100 and CGCCA) were treated with SC-43 to determine their sensitivity to SC-43-induced cell death and apoptosis. We found that SC-43 activated SH2 domain-containing phosphatase 1 (SHP-1) activity, leading to p-STAT3 and downstream cyclin B1 and Cdc2 downregulation, which induced G2-M arrest and apoptotic cell death. Importantly, SC-43 augmented SHP-1 activity by direct binding to N-SH2 and relief of its autoinhibition. Deletion of the N-SH2 domain (dN1) or point mutation (D61A) of SHP-1 counteracted the effect of SC-43-induced SHP-1 phosphatase activation and antiproliferation ability in CCA cells. In vivo assay revealed that SC-43 exhibited xenograft tumor growth inhibition, p-STAT3 reduction and SHP-1 activity elevation. In conclusion, SC-43 induced apoptosis in CCA cells through the SHP-1/STAT3 signaling pathway.
format Online
Article
Text
id pubmed-5630313
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56303132017-10-12 Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma Hu, Ming-Hung Chen, Li-Ju Chen, Yen-Lin Tsai, Ming-Shen Shiau, Chung-Wai Chao, Tzu-I Liu, Chun-Yu Kao, Jia-Horng Chen, Kuen-Feng Oncotarget Research Paper Sorafenib is a multiple kinase inhibitor which targets Raf kinases, VEGFR, and PDGFR and is approved for the treatment of hepatocellular carcinoma (HCC). Previously, we found that p-STAT3 is a major target of SC-43, a sorafenib derivative. In this study, we report that SC-43-induced apoptosis in cholangiocarcinoma (CCA) via a novel mechanism. Three CCA cell lines (HuCCT-1, KKU-100 and CGCCA) were treated with SC-43 to determine their sensitivity to SC-43-induced cell death and apoptosis. We found that SC-43 activated SH2 domain-containing phosphatase 1 (SHP-1) activity, leading to p-STAT3 and downstream cyclin B1 and Cdc2 downregulation, which induced G2-M arrest and apoptotic cell death. Importantly, SC-43 augmented SHP-1 activity by direct binding to N-SH2 and relief of its autoinhibition. Deletion of the N-SH2 domain (dN1) or point mutation (D61A) of SHP-1 counteracted the effect of SC-43-induced SHP-1 phosphatase activation and antiproliferation ability in CCA cells. In vivo assay revealed that SC-43 exhibited xenograft tumor growth inhibition, p-STAT3 reduction and SHP-1 activity elevation. In conclusion, SC-43 induced apoptosis in CCA cells through the SHP-1/STAT3 signaling pathway. Impact Journals LLC 2017-05-10 /pmc/articles/PMC5630313/ /pubmed/29029413 http://dx.doi.org/10.18632/oncotarget.17779 Text en Copyright: © 2017 Hu et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Hu, Ming-Hung
Chen, Li-Ju
Chen, Yen-Lin
Tsai, Ming-Shen
Shiau, Chung-Wai
Chao, Tzu-I
Liu, Chun-Yu
Kao, Jia-Horng
Chen, Kuen-Feng
Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma
title Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma
title_full Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma
title_fullStr Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma
title_full_unstemmed Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma
title_short Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma
title_sort targeting shp-1-stat3 signaling: a promising therapeutic approach for the treatment of cholangiocarcinoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630313/
https://www.ncbi.nlm.nih.gov/pubmed/29029413
http://dx.doi.org/10.18632/oncotarget.17779
work_keys_str_mv AT huminghung targetingshp1stat3signalingapromisingtherapeuticapproachforthetreatmentofcholangiocarcinoma
AT chenliju targetingshp1stat3signalingapromisingtherapeuticapproachforthetreatmentofcholangiocarcinoma
AT chenyenlin targetingshp1stat3signalingapromisingtherapeuticapproachforthetreatmentofcholangiocarcinoma
AT tsaimingshen targetingshp1stat3signalingapromisingtherapeuticapproachforthetreatmentofcholangiocarcinoma
AT shiauchungwai targetingshp1stat3signalingapromisingtherapeuticapproachforthetreatmentofcholangiocarcinoma
AT chaotzui targetingshp1stat3signalingapromisingtherapeuticapproachforthetreatmentofcholangiocarcinoma
AT liuchunyu targetingshp1stat3signalingapromisingtherapeuticapproachforthetreatmentofcholangiocarcinoma
AT kaojiahorng targetingshp1stat3signalingapromisingtherapeuticapproachforthetreatmentofcholangiocarcinoma
AT chenkuenfeng targetingshp1stat3signalingapromisingtherapeuticapproachforthetreatmentofcholangiocarcinoma